Insulet Advances Automated Insulin Delivery Systems for Type 2 Diabetes

Insulet Corporation, a leader in tubeless insulin pump technology, has reported significant progress in its automated insulin delivery (AID) systems, particularly for patients with Type 2 diabetes. The company's Chief Product and Customer Experience Officer, Eric Benjamin, shared updates on user adoption, clinical outcomes, and future developments at the recent American Diabetes Association's Scientific Sessions.

Expanded Indication Drives Adoption in Type 2 Diabetes

Following the Food and Drug Administration's expanded indication for Insulet's Omnipod 5 AID system to include Type 2 diabetes patients in August, the company has seen a notable increase in adoption. Benjamin revealed that over 30% of new patient starts in the first quarter of 2025 were individuals with Type 2 diabetes, highlighting the system's growing appeal beyond its traditional Type 1 diabetes user base.

The Omnipod 5 system, which adjusts insulin doses based on continuous glucose monitor readings, has demonstrated positive outcomes for users. A new analysis of the SECURE-T2D pivotal trial, presented at the ADA conference, showed that the system reduced diabetes distress in users over a 13-week period. This improvement was measured using a questionnaire assessing concerns about blood sugar management, long-term health, and daily diabetes care demands.

Development of Next-Generation AID Systems

Insulet is actively developing more advanced AID systems to further improve diabetes management. The company is currently enrolling patients for its STRIVE study, which will test a new hybrid closed-loop system. This next-generation device promises enhanced features, including a lower blood glucose set point, increased personalization options, and quality of life improvements.

Looking further ahead, Insulet is working on a fully closed-loop system for Type 2 diabetes patients. Benjamin announced plans to initiate the second set of EVOLUTION studies for this program in the latter half of the year. The company's focus on Type 2 diabetes for its closed-loop system is strategic, given the lower risk of hypoglycemia compared to Type 1 diabetes.

"The most salient thing we learned in the first set of studies is that we can do this in a reasonable timeline for people with Type 2 diabetes," Benjamin stated, emphasizing the company's progress in this area.

Market Competition and Future Outlook

As Insulet advances its AID technology, the company faces increasing competition in the patch pump market. Competitors such as Tandem, Medtronic, and Beta Bionics are developing their own patch pump systems. However, Benjamin remains confident in Insulet's market position, stating that "imitation is the finest form of flattery."

To maintain its leadership, Insulet is focusing on continuous innovation and improving accessibility of its technology. The company's recent appointment of Ashley McEvoy as CEO in April is expected to drive the next phase of growth and technological advancement.

While Insulet continues to make strides in Type 2 diabetes management, Benjamin noted that fully automated systems for Type 1 diabetes might require faster-acting insulins to be truly effective. This insight highlights the ongoing challenges and opportunities in the field of automated insulin delivery.